semaglutide product information Wegovy® 0.5 mg / 0.5 mL Injection 4 Obesity | Novo Nordisk U.S.

Stopping semaglutide abruptly often leads to rapid rebound, with reports of a 50% increase in appetite within the first week, and about 70% of patients experience weight regain after abrupt discontinuation

CMS announced changes to Medicare coverage of GLP-1 medications are not expected to affect Medicaid coverage of the medications under the BALANCE model

These FDA-approved medications have been a game-changer in the field of weight loss, effectively reducing hunger and leading to significant weight loss

Sensitive skin does not contraindicate lipotropic injections injection site reactions occur in subcutaneous tissue, not surface skin layers